Join the Opioid Overdose group to help and get support from people like you.
Opioid Overdose News (Page 3)
Higher Buprenorphine Doses Reduce Acute Care for Opioid Use Disorder
WEDNESDAY, Oct. 2, 2024 – Higher doses of buprenorphine for patients with opioid use disorder (OUD) are associated with lower acute care utilization, according to a study published online Sept. 25...
Few U.S. Jails Offer Medications for Opioid Use Disorder
TUESDAY, Sept. 24, 2024 – Few U.S. jails offer medications for opioid use disorder (MOUD), according to a study published online Sept. 24 in JAMA Network Open. Elizabeth Flanagan Balawajder, M.P.H.,...
Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder
WEDNESDAY, Sept. 25, 2024 – For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose compared with other...
Could Ozempic Help Prevent Opioid Overdoses?
WEDNESDAY, Sept. 25, 2024 – In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid o...
'Before Medically Advised' Discharge Linked to Risk for Overdose
MONDAY, Sept. 23, 2024 – 'Before medically advised' (BMA) discharge from the hospital is associated with an increased risk for subsequent drug overdose, according to a study published online Sept....
Trends in Prehospital Encounters for Youth Opioid Overdose Identified
WEDNESDAY, Sept. 18, 2024 – Prehospital encounters for youth opioid overdoses increased before the COVID-19 pandemic, then increased with onset, and then stabilized, according to a research letter...
FDA Approves Zurnai (nalmefene hydrochloride) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose
STAMFORD, Conn., August 7, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the Zurnai (nalmefene i...
FDA Approves RiVive (naloxone hydrochloride) Over-the-Counter Nasal Spray for the Emergency Treatment of Opioid Overdose
Pittsburgh, Pennsylvania--(Newsfile Corp. - July 28, 2023) - Harm Reduction Therapeutics (HRT), Inc., a nonprofit pharmaceutical company, announced today that FDA has approved OTC RiVive™ (naloxone H...
FDA Approves Opvee (nalmefene hydrochloride) Prescription Nasal Spray to Reverse Opioid Overdose
RICHMOND, Va., May 22, 2023 /PRNewswire/ – Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved Opvee® (nalmefene) nasal spray for the emergency t...
FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ Narcan Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
GAITHERSBURG, Md., March 29, 2023 (GLOBE NEWSWIRE) – Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved Narcan® Naloxone HCl Nasal ...
FDA Approves Zimhi (naloxone hydrochloride) Injection for the Treatment of Opioid Overdose
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) – Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ Zimhi™ (naloxone HC...
FDA Approves Kloxxado (naloxone hydrochloride) Nasal Spray for Emergency Treatment of Opioid Overdose
LONDON, April 30, 2021 /PRNewswire/ – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the approval of Kloxxado (naloxone hydrochloride) nasal spray 8mg, by the...
FDA Medwatch Alert: Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter
ISSUE: Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe...
Narcan (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration
January 25, 2017 – Dublin, Ireland – Today, the U.S. Food and Drug Administration (FDA) approved Narcan Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid ove...
FDA Medwatch Alert: Morphine Sulfate 0.5 mg/mL Preservative Free in 0.9 percent Sodium Chloride by by Pharmakon Pharmaceuticals: Recall - Super-potent Product
ISSUE: FDA is alerting health care professionals of a voluntary recall of morphine sulfate 0.5 mg/mL preservative free in 0.9% sodium chloride, 1 mL syringe, CII, for intravenous use made and...